Journal of Clinical Epidemiology
Volume 52, Issue 7 , Pages 609-613 , July 1999

Hospital Mortality from Acute Myocardial Infarction Has Been Modestly Reduced after Introduction of Thrombolytics and Aspirin: Results from a New Analytical Approach

  • Åsmund Reikvam

      Affiliations

    • Research Forum, Ullevål University Hospital, Oslo, Norway
    • Corresponding Author InformationAddress correspondence to: Åsmund Reikvam, MD, Research Forum, Ullevål University Hospital, 0407 Oslo, Norway
    • ,
  • lvar Aursnes

      Affiliations

    • Department of Pharmacotherapeutics, University of Oslo, Oslo, Norway
    • ,
  • for the European Secondary Prevention Study Group

      Affiliations

,Accepted 8 March 1999.

References 

  1. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardio) . Effectiveness of intravenous thrombolytic treatment in myocardial infarction. Lancet. 1986;1:398–402
  2. ISIS-2 (Second International Study of Infarct Survival) Collaborate Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction (ISIS-2). Lancet. 1988;2:349–360
  3. AIMS (APSAC Intervention Mortality Study) Trial Study Group . Effect of intravenous APSAC on mortality after acute myocardial infarction (Preliminary report of a placebo controlled clinical trial). Lancet. 1988;1:545–549
  4. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (Anglo-Scandinavian Study of Early Thrombolysis (ASSET)). Lancet. 1988;2:525–530
  5. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl J Med. 1993;329:673–682
  6. Fibrinolytic Trialists’ Collatorative Group . Indicators for fibrinolytic therapy in suspected acute myocardial infarction (Collaborative overview of early mortality and major morbidity results from all randomised trials for more than 100 000 patients). Lancet. 1994;343:311–322
  7. Goldberg RJ, Gorak EJ, Yarzebski Y, Hosmer DW, Dalen Å, Gore JM, et al.  A community wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction in out-of-hospital deaths caused by coronary heart disease. Circulation. 1993;87:1947–1953
  8. Lövel H, Dobson A, Keil V, Herman B, Hobbs MS, Stewart A, et al.  Coronary heart disease case fatality in four countries. A community study. Circulation. 1993;88:2524–2531
  9. Stevenson R, Ranjadaylan K, Wilkinson P, Roberts R, Timmis AD. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J. 1993;307:349–353
  10. Naylor CD, Chen E. Population-wide mortality trends among patients hospitalized for acute myocardial infarction (The Ontario experience, 1981 to 1991). J Am Coll Cardiol. 1994;24:1431–1438
  11. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Recent trends in hospital mortality of acute myocardial infarction—the Worcester Heart Attack Study. Have improvements been realized for all age groups?. Arch Intern Med. 1994;154:2202–2208
  12. Greenbaum RA, Morris R, Sritara P, Shanit D, Chan KL. Reduced in-hospital mortality from acute myocardial infarction with general adoption of thrombolytic treatment in the North West Thames health region. Br Heart J. 1995;74:493–496
  13. European Secondary Prevention Study Group . Translation of clinical trials into practice (A European population-based study of the use of thrombolysis for acute myocardial infarction). Lancet. 1996;347:1203–1207
  14. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction (Reappraisal of the golden hour). Lancet. 1996;348:771–775
  15. Reikvam Å, Abdelnoor M. Thrombolytic therapy for acute myocardial infarction in older patients. Lancet. 1996;347:840
  16. Krumholz HM, Murillo JR, Chen J, Vacarino V, Radford MJ, Ellerbeck EF, et al.  Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA. 1997;277:1683–1688
  17. Burrell CJ, Skehan JD, Cowley ML, Barrett CW, Mills PG. Districts’s use of thrombolytic agents. Br Med J. 1990;300:237–238
  18. Pashos CL, Normand SL, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction, 1988 to 1992. J Am Coll Cardiol. 1994;23:1023–1090
  19. Ketley D, Woods KL. Impact of clinical trials on clinical practice (Example of thrombolysis for acute myocardial infarction). Lancet. 1993;342:891–894
  20. Lamas G, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E, et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?. N Engl J Med. 1992;327:241–247
  21. Krumholz HM, Radford MJ, Ellerbeck EF, Hennen J, Meehan TP, Petrillo M, et al.  Aspirin for secondary prevention after acute myocardial infarction in the elderly (Prescribed use and outcomes). Ann Intern Med. 1996;124:292–298
  22. Brown N, Young T, Gray D, Skene AM, Hampton JR. Inpatient deaths from acute myocardial infarction, 1982–92 (Analysis of data in the Nottingham heart attack register). Br Med J. 1997;315:159–164

PII: S0895-4356(99)00042-6

Journal of Clinical Epidemiology
Volume 52, Issue 7 , Pages 609-613 , July 1999

Article Tools